Explore ViiV Healthcare
Our medicines
Product brand name (generic name) |
Class |
---|---|
3TC (lamivudine) | Nucleoside reverse transcriptase inhibitor (NRTI) |
Cabenuva (cabotegravir/rilpivirine) | lntegrase inhibitor (INI) and Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
Celsentri (maraviroc) | CCR5 antagonist |
Combivir (lamivudine/zidovudine) | Nucleoside reverse transcriptase inhibitor (NRTI) |
Dovato (dolutegravir/lamivudine) | lntegrase inhibitor (INI) and Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
Juluca (dolutegravir/rilpivirine) | Integrase inhibitor (INI) and Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
Kivexa (abacavir/lamivudine) | Nucleoside reverse transcriptase inhibitor (NRTI) |
Retrovir (zidovudine) | Nucleoside reverse transcriptase inhibitor (NRTI) |
Rukobia (fostemsavir) | Attachment inhibitor (AI) |
Telzir (fosamprenavir) | Protease inhibitor (PI) |
Tivicay (dolutegravir) | Integrase inhibitor (INI) |
Triumeq (dolutegravir/abacavir/lamivudine) | Integrase inhibitor (INI) and Nucleoside reverse transcriptase inhibitor (NRTI) |
Trizivir (abacavir/lamivudine/zidovudine) | Nucleoside reverse transcriptase inhibitor (NRTI) |
Vocabria (cabotegravir) | Integrase Inhibitor (INI) |
Ziagen (abacavir) | Nucleoside reverse transcriptase inhibitor (NRTI) |
Date of preparation: August 2021. PM-AU-HVX-WCNT-210005